Novo Nordisk alleges fraud in the $1.3 billion KBP Biosciences deal

Novo Nordisk, the maker of Wegovy and Ozempic, has accused Singapore-based KBP Biosciences of fraud over a $1.3 billion deal for the hypertension drug ocedurenone, according to a ruling from the Singapore International Commercial Court made public on February 18, 2025.^[1] Novo Nordisk is seeking as much as $830 million in damages and has already won a freeze on the worldwide assets of KBP and its founder, Huang Zhenhua.^[1]

The dispute traces back to October 2023, when Novo Nordisk agreed to buy ocedurenone from KBP for up to $1.3 billion. The drug was meant to treat uncontrolled hypertension, with possible use in cardiovascular and kidney disease.^[1] By June 2024, Novo Nordisk said it was booking a loss of about 5.7 billion Danish crowns, or roughly $800 million, tied to the drug after clinical trial results came back poorly.^[1]

Judge Philip Jeyaretnam wrote in the ruling that Novo Nordisk "has shown that it has a good arguable case against KBP for fraud under New York law, which governs the dispute."^[1] The judge said it was arguable that "KBP knowingly failed to disclose material information," including internal analysis of trial results that pointed to the drug's "inefficacy" before the deal closed.^[1] The court said Novo Nordisk will pursue arbitration against KBP in New York.^[1] Neither Novo Nordisk nor KBP Biosciences responded to Reuters' request for comment, and Huang was not immediately reachable.^[1]

Why it matters for patients

Ocedurenone is a hypertension drug, not a GLP-1 medicine, so this lawsuit does not directly affect people using Wegovy, Ozempic, or Rybelsus. But the case matters to patients in an indirect way. Novo Nordisk already recognized an $800 million loss tied to this deal in mid-2024, a sum large enough to show up in the company's financial results.^[1] When a major drugmaker absorbs losses like this, it can shape how much money and attention the company puts toward its broader pipeline, including cardiovascular and kidney research that overlaps with conditions many GLP-1 patients also manage.

The case is also a reminder that drug acquisitions can go wrong even after they are announced with confidence. Novo Nordisk's claim, if proven, would mean the company paid for a drug based on information that allegedly hid poor trial results. For patients following news about Novo Nordisk's product lineup, this is a business and legal story about accountability in drug deals, not a safety signal about any medicine currently on pharmacy shelves.

What happens next

The Singapore court has already frozen KBP Biosciences' and Huang Zhenhua's worldwide assets as of the ruling made public on February 18, 2025.^[1] The next major step will be arbitration proceedings that Novo Nordisk plans to bring against KBP in New York, where the underlying contract dispute will be argued under New York law.^[1] No date for that arbitration was given in the available reporting, and it is not yet known when a resolution or further financial disclosures might follow.